Cinven Pays £2.2B for Theramex, Four Times the 2018 Entry Price

Private equity firm Cinven has agreed to acquire Theramex, the women's health pharmaceutical company, from Carlyle and PAI Partners for approximately £2.2 billion. The exit represents a 4x multiple on the £550 million paid when Carlyle and PAI bought the business in 2018. The transaction marks Theramex's third private equity ownership change in seven years.

Theramex develops and markets pharmaceuticals for women's health, primarily hormone replacement therapies and menopause treatments across Europe and emerging markets. The platform generates revenue from a portfolio of prescription and over-the-counter products targeting perimenopause, menopause, and reproductive health. Carlyle and PAI acquired the company from Nordic Capital in 2018, then expanded the commercial footprint through bolt-on acquisitions in France, Italy, and the UK. The business now operates in more than 50 countries with a sales force exceeding 400 representatives. Revenue growth averaged mid-teens percentage points annually under Carlyle-PAI stewardship, driven by market expansion and the aging demographic curve in developed markets.

The valuation reflects two structural tailwinds that allocators pricing healthcare platforms must now factor. First, the women's health category has moved from niche to defensible. Institutional capital avoided the space for decades due to reimbursement uncertainty and limited product pipelines. That caution reversed after 2020, when demographic data confirmed that women aged 45 to 65 represent the fastest-growing consumer healthcare cohort in Europe and North America. Second, regulatory pathways for hormone therapies have shortened. The European Medicines Agency cut approval timelines for biosimilar HRT products by roughly 18 months since 2019, which compressed time-to-market risk for sponsors. Cinven is paying for a portfolio that benefits from both trends without requiring R&D-stage capital or patent cliffs.

The 4x markup in six years also signals that private equity's traditional hold period discipline has softened in categories with visible demand curves. Carlyle and PAI held Theramex for approximately six years, a duration once considered the floor for achieving double-digit IRRs. The exit multiple suggests either that Cinven expects material operational upside through consolidation, or that the bid reflects the scarcity value of platforms with recurring revenue in women's health. Most comparable women's health assets that came to market in the past 18 months drew multiple bidders, and several transacted above 12x EBITDA. Theramex's exit likely sits in that range, though neither Cinven nor the sellers disclosed the EBITDA base.

Operators and allocators should monitor Cinven's post-close integration roadmap, particularly any bolt-on M&A targeting smaller women's health brands in Southern Europe and Latin America. The firm has previously deployed this strategy in specialty pharma, acquiring and integrating three to five regional brands within 12 to 18 months of closing a platform deal. Watch also for any partnership announcements with branded pharmaceutical companies seeking to divest non-core women's health divisions. Those divestitures typically emerge six to nine months after a large platform acquisition, as corporates reassess portfolio fit.

The deal closes in Q2 2025, subject to regulatory clearance. Cinven has not yet named the portfolio company CEO or disclosed whether Theramex's existing management will roll equity. The absence of that detail this early suggests negotiations on incentive structure are ongoing.